A systems pharmacology model was constructed during preclinical drug development to assist in understanding the potential druggability risks of FAAH inhibitors for pain relief. In doing so, the model highlights gaps in our biological knowledge and suggests that further understanding may be necessary to further this therapeutic avenue against osteoarthritic pain.
New page listing all models (from the curated and non-curated branches) which are related to diseases.
More models, new and updated features. For more information, please refer to the release notes.
BioModels: Content, Features, Functionality, and Use published in CPT: Pharmacometrics & Systems Pharmacology